BG-12: Updated data from phase III studies


REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, NEW ORLEANS LA, APRIL 21-28, 2012 – The efficacy and safety of the oral fumarate BG-12 has been evaluated in the phase III studies DEFINE and CONFIRM (see BG-12 in RRMS: DEFINE trial, NeuroSens, October 21, 2011; CONFIRM – Second phase III trial results for BG-12, NeuroSens, November 30, 2011). New data from both trials were presented at AAN.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page